<DOC>
	<DOCNO>NCT00679484</DOCNO>
	<brief_summary>This study compare olmesartan medoxomil candesartan cilexetil reduce BNP , prognostic biomarker heart failure , week 24</brief_summary>
	<brief_title>Study Demonstrate Non-inferiority Olmesartan Medoxomil Versus Candesartan Cilexetil Reducing Blood B-type ( Brain ) Natriuretic Peptide Levels Week 24</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>Male female , adult , outpatient age 18 85 year Patients document hospital admission within previous 3 month randomization discharge diagnosis CHF Patients functional NYHA class IIIV LVEF &lt; 40 % assess within last 3 month Patients blood BNP level &gt; 400 pg/ml NTProBNP level &gt; 1500 pg/ml Patients CHF due ischemic heart disease , idiopathic dilate cardiomyopathy ( IDC ) , mitral aortic insufficiency hypertension Patients stable conventional treatment diuretic , ACEI and/or betablockers and/or aldosterone antagonist least 2 month prior randomisation , unless document contraindication intolerance Females pregnant plan pregnancy time trial , nurse childbearing potential use acceptable method contraception . If female becomes pregnant study , withdrawn immediately Patients current hospitalisation due heart failure Patients stroke transient ischemic attack ( TIA ) within last 3 month Patients acute coronary syndrome , myocardial infarction , coronary artery bypass angioplasty within 3 month Planned cardiac surgery , revascularization resynchronization within study period Patients operable valvular disease significant obstructive cardiomyopathy Patients bradycardia [ heart rate ( HR ) &lt; 50 bpm ] Patients hypotension [ systolic blood pressure ( SBP ) &lt; 90 mmHg ] Patients obstructive pneumopathy Patients clinical significant renal failure ( creatininemia &gt; 200 micromol/l )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>